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Abstract 
Scope: The gut microbiota might be a critical modifier of metabolic disease development. Dietary 
fibers such as galacto-oligosaccharides (GOS) presumably stimulate the growth of bacteria beneficial 
for metabolic health. This study aimed to assess the impact of GOS on obesity, glucose and lipid 
metabolism. 
Methods&results: Following Western-type diet feeding (C57BL/6 mice) with or without β-GOS (7% 
w/w, 15 weeks), body composition, glucose and insulin tolerance tests, lipid profiles, fat kinetics 
studies and microbiota analyses were performed. GOS reduced body weight gain (p<0.01), 
accumulation of epididymal (p<0.05) and perirenal (p<0.01) fat, and development of insulin 
resistance (p<0.01). GOS-fed mice had lower plasma cholesterol (p<0.05), mainly within low-density 
lipoproteins, lower intestinal fat absorption (p<0.01), more fecal neutral sterol excretion (p<0.05). and 
higher intestinal GLP-1 expression (p<0.01). Fecal bile acid excretion was lower (p<0.01) in GOS-fed 
mice with substantial compositional differences, namely decreased cholic (p<0.05), α-muricholic 
(p<0.05), and deoxycholic acid excretion (p<0.01), whereas hyodeoxycholic acid increased (p<0.01). 
Substantial changes in microbiota composition, conceivably beneficial for metabolic health occured 
upon GOS feeding.  
Conclusion: GOS supplementation to Western-type diet improved body weight gain, dyslipidemia 
and insulin sensitivity supporting a therapeutic potential of GOS for individuals at risk of developing 
metabolic syndrome. 
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Graphic Abstract 
Dietary fibers such as galacto-oligosaccharides (GOS) stimulate the growth of beneficial 
bacteria which can modulate metabolic disease development. Western-style diets have largely 
contributed to the development of metabolic syndrome-related diseases. The present study in 
mice demonstrates that GOS supplementation to a “Western” diet reduces body weight gain 
and improves other metabolic syndrome-related parameters by, at least in part, decreasing 





www.mnf-journal.com Page 4 Molecular Nutrition & Food Research 
This article is protected by copyright. All rights reserved. 
4 
Introduction 
The world population is facing an epidemic of metabolic syndrome-related disease, largely 
due to a growing consumption of “Western” diets and a sedentary lifestyle [1]. Unhealthy nutrition 
induces obesity with an associated increase in oxidative stress, fat accumulation, inflammation, and 
insulin resistance among other metabolic dysregulations. Chronic non-communicable diseases such as 
type 2 diabetes, non-alcoholic fatty liver disease and cardiovascular disease are serious adverse 
consequences of prolonged exposure to such conditions [2, 3]. Accumulating observations indicate 
that changes in gut microbiota composition induced by Western-style diets play an important role in 
modifying the development of metabolic syndrome. Significant shifts in microbiota composition have 
been associated with inflammation, obesity and metabolic dysregulation [4]. 
Dietary fibers are a vital source of energy for gut microbial populations. Fibers have been 
shown to influence the composition of the gut microbiota and thereby the production of bioactive 
metabolites such as short-chain fatty acids (SCFA), secondary bile acids, vitamins and more. These 
bioactive metabolites have been suggested to exert various metabolic effects on the host [5].  
Galacto-oligosaccharides (GOS) are dietary fibers derived from lactose using either α- or β-
galactosidase enzymes [6]. GOS is a soluble fiber widely used for its potential to alter gut microbiota 
composition by stimulating growth of bacteria supposedly beneficial for metabolic health such as 
members of the genera Bifidobacterium and Lactobacillus. Different varieties of GOS have been 
utilized in a limited number of clinical studies. Under free living conditions it has been shown that 
GOS supplementation in healthy elderly as well as overweight volunteers can lead to altered gut 
microbiota composition and improvement of biomarkers of systemic inflammation [7, 8], while no 
improvements of glucose tolerance were detected either by clamp techniques in obese, prediabetic 
subjects receiving β-GOS [9] or by OGTT in healthy, young volunteers receiving α-GOS [10]. 
However, thus far the long-term effects of GOS on the development of obesity and insulin resistance 
on the background of a Western-type high fat diet have neither been studied in humans nor in 
preclinical models. Therefore, the present work aimed to investigate long-term metabolic effects of β-
GOS supplementation to a Western-type diet in vivo in mice, including an evaluation of potential 
underlying mechanisms.   
www.mnf-journal.com Page 5 Molecular Nutrition & Food Research 
This article is protected by copyright. All rights reserved. 
5 
Materials and Methods 
Animal experimental design 
Male C57BL/6OlaHsd mice were obtained from Harlan (Horst, The Netherlands). At the start 
of the dietary intervention all mice were 9 weeks of age. All mice were housed individually in a light- 
and temperature-controlled facility (12h light-dark cycle, 12°C). All animal experimentations were 
approved by the Committee of Animal Experimentation at the University of Groningen (permit # 
6905) and performed in accordance with the Dutch National Law on Animal Experimentation (Wod) 
as well as international guidelines on animal experimentation. Vivinal® GOS powder 
(FrieslandCampina, The Netherlands) was generously provided by Dr. Henk Schols (Wageningen 
University & Research, The Netherlands). The product contained 70% (w/w) β-GOS (main structural 
element: β-D-Galp-(1->4)), 24% (w/w) lactose and 6% (w/w) monosaccharides (glucose and 
galactose). The control high-fat baseline diet (27% fat; energy 21.3 MJ/kg) was from Ssniff diets 
(Soest, Germany) and GOS supplemented diet (27% fat; energy 21.3 MJ/kg) was obtained by 
replacing an equal amount of corn starch with GOS (7% [w/w], for detailed composition see 
Supplemental Table S1). Animals were fed ad libitum with control (n=8) and GOS (n=8) 
supplemented diets for a period of 16 weeks. Animals were weighed every week. Food intake was 
measured after 8 and 15 weeks. At the end of the dietary intervention the gastrointestinal tract, liver 
and adipose tissues were excised, collected and stored at -80 °C until later analysis. Power analysis 
indicated that with an assumption of 80% power and a two-sided α significance of 0.05 the study was 
sufficiently powered with group sizes of n=8 to detect the observed difference in body weight as 
outcome parameter. The study was repeated with an identical set-up to confirm the obtained results as 
well as to add determinations such as indirect calorimetry (see below). 
Analysis of plasma and liver 
Blood samples were collected by heart puncture at the time of termination. Plasma was 
isolated and aliquots were stored at -80 °C until further analysis. For lipoprotein fraction analysis, 
plasma samples were pooled and subjected to fast protein liquid chromatography (FPLC) gel filtration 
using a Superose 6 column (GE Health, Uppsala, Sweden) as described previously [11]. Bligh and 
Dyer procedure was used to extract lipids from liver homogenates which were then subsequently 
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redissolved in water containing 2% Triton X-100 as described previously [12]. Commercially 
available reagents (Roche, Diagnostic, Basel, Switzerland) were used to measure plasma and hepatic 
total cholesterol and triglycerides [13]. 
Fecal mass sterol, fatty acids, bile and short-chain fatty acids measurements  
Fecal samples were obtained from the bedding following collection over a 24 h period. The 
samples were dried, weighed and ground. 50 mg of ground feces was used for extraction of neutral 
sterols and bile acids. A mixture of acetyl chloride and trimethylsilytate with pyridine, N, O-Bis 
(trimethylysilyl) trifluoroacetamide and trimethylcholorosilane was used for methylating bile acids. 
Fecal neutral sterols and bile acids were then measured using gas-liquid chromatography as published 
earlier [12]. Cecal short-chain fatty acids and lactate were determined at the time of sacrifice by gas-
liquid chromatography as described [14] after extraction from 50mg of cecum content as detailed 
previously [15]. 
Indirect calorimetry and body composition analysis 
At the end of the dietary intervention body composition was measured using the MiniSpec 
LF90 TD-NMR analyzer (Bruker BioSpin, Billerica, MA, US). Each animal was placed inside the 
restraint tube unanesthetized and without impairing respiration. After body composition 
measurements animals were returned to their cage. One week before sacrifice body composition was 
analyzed in another cohort using a Minispec Whole Body Composition Analyser (Bruker). 
Respiratory exchange ratio (RER) and energy expenditure (EE) were determined using a 
Comprehensive Laboratory Animal Monitoring System (TSE Systems GmbH, Bad Homburg, 
Germany).  
Glucose tolerance and insulin tolerance tests 
Intraperitoneal glucose tolerance test was conducted at the end of the dietary intervention 
period by intraperitoneal administration of 2.5 g glucose per kg body weight [16]. The animals were 
fasted for six hours prior to the test. For intraperitoneal insulin tolerance tests, animals were fasted for 
four hours prior to the intraperitoneal injection of insulin (Novo Nordisk, Denmark) at 0.75 unit/kg 
body weight. 
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Electron microscopy 
At the time of sacrifice, small pieces (~3-5mm) of brown adipose tissue were cut and fixed in 
0.1% glutaraldehyde (GA) in 0.1M sodiumcacodylate buffer. Following overnight fixation at 4°C, 
tissue was embedded in EPON using standard procedures [17]. Images were taken using 3400X 
magnification in a transmission electron microscope (CM100; FEI Company, The Netherlands) at 
80KV.  
Assessment of fat absorption kinetics  
At the end of the dietary intervention mice were fasted overnight and then given an 
intraperitoneal injection with poloxamer 407 (P407, 1 g/kg body weight), which completely inhibits 
the catabolism of apolipoprotein B-containing lipoproteins. Immediately after, an intragastric load of 
150 µl olive oil was given by gavage. Subsequently, blood samples were collected into heparinized 
tubes from the retro-orbital plexus at time 0, 2 and 4 hours. Plasma triglycerides were measured using 
the reagents mentioned above and since triglyceride catabolism is inhibited by P407 changes in 
plasma levels are a reflection of absorption rates. 
Quantitative real-time PCR gene expression analysis 
 Total RNA extraction was performed using TriReagent (Sigma). Nanodrop ND-100UW-vis 
spectrometer (NanoDrop Technologies Wilmington DE) was used to measure the RNA concentration. 
cDNA was synthesized with one µg of RNA using Invitrogen (Carlsbad CA) reagents. ABI Prism 
7700 machine (Applied Biosystem, Damstadt Germany) was used to perform real time PCR using the 
synthesized cDNA and primers designed by Eurogentec (Seraing, Belgium). To calculate the 
individual relative mRNA expression, 36B4 gene expression was used as a housekeeping gene, and 
values were further normalized to the relative expression of the individual control group [13].  
Glp-1 determination 
 Glp-1 was measured by ELISA in plasma that was immediately frozen after collection 
without addition of a protease inhibitor, following the manufacturer´s instruction (EMD Millipore, St. 
Louis, MO, USA). 
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Microbiota analysis 
Total bacterial DNA was extracted from 0.01-0.1g of cecal contents using the double bead-
beating procedure as previously described [18]. Briefly, the V4 regions of 16S ribosomal RNA 
(rRNA) genes were PCR amplified with uniquely barcoded primer pair: 515F (5’-
GTGCCAGCMGCCGCGGTAA) - 806R (5’-GGACTACHVGGGTWTCTAAT), and the barcoded 
PCR products were then purified and pooled into an amplicon library containing 100 ng of each 
sample. The pool was adjusted to 100 ng/µL final concentration and sent for adapter ligation and 
Illumina HiSeq2000 sequencing at GATC-Biotech, Konstanz, Germany [18]. The 16S rRNA gene 
sequencing data was analyzed using the NG-Tax analysis pipeline [19] with standard parameters and 
SILVA_128_SSU 16S rRNA gene reference database (https://www.arb-silva.de/) to assign taxonomy 
[20].  
Statistics 
Statistical analysis for the physiological parameters was performed using GraphPad Prism software 
(San Diego, CA). All data are presented as means ± SEM. Statistical significance was assessed using 
the Mann-Whitney U-test and was assigned to p<0.05. With respect to the microbiome, microbiota 
alpha diversity indices (Shannon, Chao1, and PD Whole Tree) were calculated on rarefied read data 
(cutoff = 50,000 reads/sample) and compared between treatment groups using a nonparametric two 
sample t-test with Monte Carlo permutations in QIIME [21]. Weighted and unweighted unifrac 
distances were calculated and compared using ANOSIM test (QIIME). Differentially abundant taxa 
between treatment groups were identified using Kruskal-Wallis analysis (QIIME). Unconstrained 
(PCA) and constrained redundancy analysis (RDA) was carried out in Canoco5, with significance 
assessed using a permutation test [22]. Resulting p values in the RDA analysis were corrected for 
multiple comparisons using FDR method with significance cutoff set at FDR<0.05. Biomarker taxa 
associated with different dietary treatments at significance cutoff p<0.01 were identified and 
visualized using LefSe modules incorporated into Galaxy [23]. Spearman correlations were calculated 
in R (version 3.4.3) to evaluate associations between the relative abundance of different microbial 
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genera and levels of metabolic biomarkers in plasma and feces. Correlations passing the threshold ct = 
±0.7 and the significance cutoff of p<0.05 were visualized using the pheatmap function in R.  
Results 
Dietary GOS supplementation reduced the development of body weight gain, 
dyslipidemia and insulin resistance 
Prior to the dietary intervention both groups of animals were matched for age and body 
weight. The GOS-containing diet was tolerated well, mice did not experience loose stools or had any 
other visible abnormality; physical activity was not different from the control group (control vs GOS-
fed mice during the day, 13.5 ± 6.5 vs 13.7. ± 5.7 m, P=0.97; during the night, 25.8 ± 7.5 vs 22.0 ± 
7.6 m, P=0.48). A significantly lower body weight gain (between 3-12%, Fig. 1A, p<0.01) was 
observed from the second week onwards, while food intake in both groups remained unchanged (Fig. 
1B). Using NMR analysis a lower fat mass was observed in GOS-fed mice compared to the control 
group, but the difference did not reach statistical significance (-17%, Fig. 1C, p=0.055). Upon 
sacrifice, weighing of individual fat depots demonstrated that GOS feeding lead to significantly lower 
epididymal (-12%, p<0.05) and perirenal (-29%, p<0.01) fat accumulation (Fig. 1D). Glucose 
tolerance tests performed at the end of the dietary intervention indicated no differences between the 
groups (Fig. 1E). Development of insulin resistance, however, was reduced in the GOS supplemented 
groups (Fig. 1F) with the area under the curve (AUC) being significantly lower in GOS fed animals (-
20%, Fig. 1G, p<0.05). Interestingly, GOS supplementation increased in the proximal intestine the 
mRNA expression of proglucagon, the gene encoding glucagon-like peptide-1 (Glp-1), an incretin 
hormone responsible for stimulating insulin secretion, which is subsequently generated by proteolytic 
processing (+66%, Table 1, p<0.001). Correspondingly, circulating Glp-1 levels were higher in GOS-
fed mice compared with controls (2.62±0.25 vs. 1.30±0.15 ng/l, respectively, p<0.01). Cecal levels of 
the short-chain fatty acids acetate (45.9±5.3 vs. 27.1±2.5 µmol/g, respectively, p<0.05) and butyrate 
(9.6±1.3 vs. 5.1±0.7 µmol/g, respectively, p<0.05) as well as levels of lactate (10.1±1.3 vs. 4.3±1.2 
µmol/g, respectively, p<0.01) were higher in the GOS receiving group, while propionate levels 
showed no significant change (13.7±2.0 vs. 9.1±1.4 µmol/g, respectively). 
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At the end of the dietary intervention, plasma total cholesterol was lower in the GOS-fed 
group (-20%, Fig. 1H, p<0.05). FPLC analysis of the plasma indicated that the reduction in total 
cholesterol was largely contributed by a reduction in low-density lipoprotein (LDL) particles in GOS-
fed mice (Fig.1I). This change in plasma lipids occurred in the face of decreased LDL receptor mRNA 
expression in the liver of the GOS receiving mice (Table 1). Furthermore, plasma triglyceride levels 
were significantly lower in the GOS-fed group (-40%, Fig. 1J, p<0.05). At week 15, GOS fed mice 
also showed a trend towards a lower liver/body weight ratio (Fig. 1K, p=0.06). In GOS-fed mice, 
hepatic triglyceride levels tended to be lower (-33%, IL, p<0.06), whereas hepatic cholesterol levels 
remained unchanged (Fig. 1M) compared to the control group.  
GOS supplementation did not alter energy expenditure or the respiratory exchange ratio 
In order to investigate the cause of lower body weight gain in the face of unchanged food 
intake, we first analyzed brown adipose tissue (BAT) for potential indications for a change in its 
thermogenic capacity. Electron microscopy of BAT showed no substantial change in mitochondrial 
morphology and lipid droplets (Fig. 2A). mRNA expression of several relevant genes remained 
unchanged (Fig. 2B). However, we detected a significant increase in transcription of the gene 
encoding for uncoupling protein 1 (Ucp1), a mitochondrial carrier protein of BAT involved in heat 
generation by disruption of the proton gradient during respiration (Fig. 2B, p<0.05). 
Because of the higher expression of Ucp1 we next performed indirect calorimetry to 
investigate whether mice on GOS supplementation had an altered energy metabolism. We measured 
energy expenditure (EE) and calculated respiratory exchange ratios (RER) based on oxygen 
consumption and carbon dioxide production. Both groups had comparable RER during the light hours 
when the mice were resting as well as during the night hours when the mice were active (Fig. 2C, 2D 
& 2E). Control and GOS-fed mice also showed similar EE during day and night hours (Fig. 2F & 2G). 
Thus, the increase in Ucp1 mRNA expression in BAT did not translate into a physiologically 
meaningful increase in energy metabolism. 
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GOS altered fecal neutral sterol and bile acids profiles 
 We investigated the effect of GOS on the fecal excretion of cholesterol and bile acids 
including their microbiota-derived products. At the end of the dietary intervention both groups had 
similar fecal mass output (Fig. 3A). In the neutral sterol profile of feces, cholesterol and dihydroxy 
(DiH)- cholesterol remained unchanged. In contrast, coprostanol, a major bacteria-derived product, 
was substantially higher in GOS-fed mice (+370%, Fig. 3B, p<0.05) translating into an overall 
significant increase in total fecal neutral sterol excretion in GOS supplemented mice compared to the 
control group (+50%, Fig. 3B, p<0.05). On the other hand, the excretion of bile acids, another major 
route for cholesterol disposal from the body, was significantly reduced in the feces of GOS-fed mice 
(-38%, Fig. 3C, p<0.01). Consistent with this suggestion of a decreased steady state bile acid 
synthesis, mRNA expression of genes that encode for two key enzymes involved in hepatic bile acid 
synthesis, namely cholesterol 7α-hydroxylase (Cyp7A1) and sterol 12-alpha-hydroxylase (Cyp8b1), 
was lower in the GOS group (Table 1). In addition to changes in mass, we also observed alterations in 
bile acid profiles (Fig 3D) with almost proportionate decreases in cholic acid (CA, -50%, p<0.05), α-
muricholic acid (α-MCA, -54%, p<0.05) and deoxycholic acid (DCA, -40%, p<0.01), while 
hyodeoxycholic acid excretion was substantially higher in GOS fed mice (HDCA, +260%, p<0.01). In 
plasma, total bile acids were moderately however, not significantly increased in GOS fed mice (Fig. 
3E, p=0.09). Relatively higher proportions of ursodeoxycholic acid (UDCA, +90%, p<0.05) and β-
muricholic acid (β-MCA, +60%, p<0.05) were present in the GOS group compared to controls (Fig. 
3F). Taurocholic acid (TCA, -65%, p<0.01) was present in a lower proportion in plasma of GOS 
supplemented mice. HDCA was detectable in the plasma of the GOS group in appreciable amounts, 
whereas it was minimal in the control group. 
Dietary supplementation of GOS delayed the appearance of enterally administered fat 
into the blood  
 In order to investigate whether GOS feeding had a potential impact on fat absorption in the 
intestine we performed an oral fat tolerance test and assessed the appearance of enterally administered 
fat into the plasma. In GOS supplemented mice, triglyceride appearance in plasma was evidently 
reduced at the two and four-hour time points suggestive for a decreased intestinal fat absorption rate 
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(Fig. 4C). The intestinal mRNA expression of genes encoding for lipid transporters, as well as factors 
contributing to chylomicron production such as microsomal triglyceride transfer protein (Mttp) and 
apolipoprotein C3 (ApoC3) remained unchanged (Table 1).   
GOS supplementation shifted the composition of cecal microbiota  
Illumina HiSeq 16S rRNA gene sequencing yielded 3,325,258 (Min: 51,558; Max: 563,39; 
Median: 175,285; Mean: 207,828.625; Std. dev.: 151,030.39) reads that passed the quality check and 
could be assigned to 278 OTUs from 59 bacterial genera. Genus level taxa detected at an average 
relative abundance above 0.001 in at least one of the treatment groups are listed in Supplemental 
Table S2. On average the three most abundant genera were Allobaculum, Faecalibaculum, and 
uncultured bacterium from Bacteroidales S24-7. The combined relative abundance of these taxa 
comprised more than 56% of all detected taxa. GOS feeding resulted in significantly higher levels of 
Actinobacteria, specifically Bifidobacterium and Parvibacter, Betaproteobacteria - Parasutterella, as 
well as Akkermansia and uncultured genus within family Erysipelotrichaceae (FDR<0.05). GOS 
supplementation was associated with a significant reduction in Firmicutes taxa, specifically within 
Clostridia, mainly in families Lachnospiraceae, Ruminococcaceae and Peptostreptococcaceae, as 
well as genera Olsenella, Alistipes, Faecalibaculum and Bilophila. Differentially abundant taxa in 
GOS and control groups identified in LefSe biomarker discovery analysis with a significance cutoff 
p<0.01 are summarized in Fig. 5A. 
Overall fewer genus level taxa were detected in the GOS treatment group animals than in the 
controls (observed species: 44 vs. 53 respectively; FDR=0.004). A significant difference was also 
detected when Chao1 species richness scores were compared (Chao1: 59 vs 90 respectively, 
FDR=0.001). GOS and control group animals also differed in their microbiota diversity (PD Whole 
Tree scores: 4.5 vs 5.0 respectively; FDR=0.019), but not when Shannon diversity indices were 
compared (3.5 vs 4.2 respectively; FDR=0.094), indicating that the control diet induced microbial 
community was more phylogenetically diverse (distant) than the community supported with GOS 
supplemented diet. Genus level based PCA analysis revealed a strong effect of diet on the cecal 
microbial communities as indicated by the clear separation of animals from different treatment groups 
(data not shown), and the results were similar when PCoA analysis was used with either weighted and 
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unweighted unifrac distances data (Supplemental Fig.1). ANOSIM analysis indicated significant 
differences between treatment groups when comparing weighted (test statistic = 0.220; FDR=0.023) 
and unweighted (test statistic = 0.880; FDR = 0.001) unifrac distances. Diet explained 42.6% variation 
in the microbiota, with vector position indicating that among other taxa, the health benefiting 
Bifidobacterium and Akkermansia were associated with GOS treatment (Fig. 5B). Furthermore, 
Spearman correlation analysis identified strong positive correlations between Bifidobacterium, 
Parvibacter, Olsenella and an uncultured genus within the Ersipelotrichaceae with intestinal 
proglucagon expression and fecal hyodeoxycholic acid. In addition, several other microbial taxa 
positively correlated with fecal deoxycholic acid (Fig. 5C). 
Discussion 
 
The results of the present study demonstrate that supplementing a “Western” type diet with β-
GOS for 15 weeks led to reduced body weight gain and subsequently decreased adiposity in mice. 
Development of insulin resistance was also reduced, conceivably as a consequence of reduced weight 
gain and adiposity. In addition, GOS-fed mice had a less atherogenic plasma lipid profile. GOS 
feeding decreased the intestinal fat absorption rate and increased intestinal GLP-1 expression. 
Combined these data, if confirmed in humans, support the use of GOS as a food supplement in the 
prevention or treatment of metabolic syndrome related disease. 
Increase in consumption of “Western” type diets has accelerated the development of obesity 
[24], and the impact of supplementing GOS as dietary fibers has, to the best of our knowledge, not 
been studied before. Dietary fibers have been reported to enhance satiety perception as well as to 
delay hunger onset. Satiety signaling hormones such as glucagon-like peptide (GLP-1) have been 
identified to influence satiation. GLP-1 is expressed in L-cells of the proximal ileum and colon and 
was reported to reduce food intake and delay gastric emptying [25]. Past studies in β-GOS fed rats 
have shown increased colonic expression of GLP-1 [26].The secretion of such hormones can be 
regulated by a variety of molecules with signaling properties. Particularly, SCFA and bile acids such 
as hyodeoxycholic acid were shown to trigger the release of satiety hormones including GLP-1 [27, 
28]. Hyodeoxycholic acid was highly increased in feces by GOS administration in the present study 
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lending further plausibility to the proposed mechanism via a shift in bile acid composition. Consistent 
with these findings we observed a decreased body weight gain in the GOS group together with an 
increased GLP-1 expression. We did not observe a decreased food intake in GOS treated mice, but a 
more direct interaction of GLP-1 with specific tissues such as the pancreas or indirectly via liver, 
adipose tissue or central nervous system circuits cannot be excluded [29, 30]. Our analysis further 
revealed that GOS feeding in animals in the presence of higher dietary fat could reduce the rate of 
intestinal fat absorption. This effect could potentially also be attributed to GLP-1, since it was shown 
that gut-derived GLP-1 can decrease intestinal chylomicron production via a gut-brain axis [31].  
Dyslipidemia is one of the major risk factors for cardiovascular disease. Dyslipidemia 
associated with obesity is characterized by increased triglycerides, increased LDL cholesterol, and 
decreased HDL cholesterol [32]. A moderate shift in the lipoprotein profile with decreased LDL 
cholesterol was found in GOS-fed animals compared to controls. The results indicate that GOS 
supplementation could prove useful in helping to normalize a proatherogenic lipoprotein profile in 
addition to e.g. statins, the current mainstay of medication in the cardiovascular field. 
Interestingly, GOS supplementation led to significant shifts in fecal sterol excretion. While 
total neutral sterol excretion was higher in GOS-fed animals compared to the control group, the fecal 
excretion of bile acids was almost proportionally decreased. Increase in fecal coprostanol in GOS fed 
animals, likely reflected a shift in intestinal bacterial populations induced by GOS since coprostanol is 
a product of bacterial metabolism. Bacterial enzymes play an important role in forming coprostanol 
by reducing the double bond between carbon 5 and 6 of cholesterol molecules [33] and also in 
converting primary into secondary bile acids. Total bile acids in feces were reduced in GOS-fed mice 
mirrored by the downregulation of hepatic Cyp7a1 and Cyp8b1 mRNA expression in GOS-fed mice, 
while the fecal bile acid profile reflected a substantial shift in different species in response to dietary 
GOS. Particularly remarkable was the high level of hyodeoxycholic acid in plasma and feces of GOS-
fed mice. In hamsters, dietary hyodeoxycholic acid was shown to decrease cholesterol absorption 
thereby lowering plasma LDL-cholesterol levels and increasing fecal cholesterol excretion [34]. We 
observed congruent physiological changes in our present mouse study in the GOS group. 
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Alterations in gut microbial populations are known to contribute to changes in host 
metabolism and to dysbiosis in particular with respect to the development of obesity [35, 36]. In the 
present study significant GOS-induced changes in cecal microbial populations were found that are in 
agreement with previous studies utilizing different GOS preparations [7, 37, 38]. A marked increase 
was observed in the relative abundance of Bifidobacterium and Akkermansia in the GOS group. Both 
of these are known to have beneficial effects on host metabolism [39, 40]. The bifidogenic effect of 
GOS was consistent with what was observed in individuals with obesity [39], however, in these GOS 
supplementation had no effect on body weight and insulin sensitivity. It was recently shown in elegant 
studies that Akkermansia improves obesity and glycemic control, although these effects might be 
strain-dependent and thus not in detail confirmable with the resolution of our study [41, 42]. 
Bifidobacterium on the other hand mostly generates acetate and lactate - consistently observed also in 
our study-, which acidify the intestinal environment and potentially restrict growth of pathogenic 
bacteria and improve mucosal barrier function [43, 44]. High-fat feeding causes reduced growth of 
Bifidobacterium species [45]. However, our study showed that supplementing a Western-type diet 
with GOS still potently stimulates Bifidobacterium growth. Gut microbial derived metabolites can 
influence various metabolic parameters [28, 46]. Our analyses also revealed significant correlations of 
bacterial species with various bile acid species, total fecal neutral excretion and intestinal GLP-1 
expression. Specifically, growth of Bifidobacterium, Parvibacter, Olsenella and Ersipelotrichaceae 
showed significant correlation with GLP-1. Given that Bifidobacterium is associated with the 
generation of acetate, GOS-feeding could potentially stimulate such a mechanism via the acetate-
mediated GLP-1 secretion pathway [47, 48]. In the interpretation of the microbiota-related results we 
feel that a potential limitation of our study needs to be pointed out. We chose for the GOS-containing 
and the control diet to have similar energy densities and replaced corn starch with GOS instead of 
comparing different fibers. Therefore, this experiment does not allow to clearly distinguish between 
effects specific to GOS from differences that could be ascribed to presence vs. absence of fibers. 
Further studies would be required to identify bacterial strains responsible for the GOS-specific effects 
on host metabolism. 
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With respect to the relevance of our findings for the human situation, thus far, to the best of 
our knowledge, only one intervention trial is available investigating the effect of β-GOS as used in our 
study on insulin sensitivity and weight gain in a limited number of prediabetic subjects. No significant 
impact on both of these parameters was seen, however, the fecal abundance of Bifidobacterium 
species increased significantly [9]. Interestingly, fecal SCFA remained unaltered, too, indicating that 
the amount of GOS used (15g/d) might have been too low to produce significant physiological 
benefits. On the other hand, no gastrointestinal side effects occurred. More work appears to be 
required in this respect. In humans dosing could represent a problem, since the occurrence of loose 
stools due to decreased fat absorption could conceivably result in reduced compliance. Another study, 
using α-GOS though reported that in young healthy adults, fasting glucose levels increased, while 
OGTT results were not impacted after a 2-week intervention [10]. Potential physiological effects of 
the different chemical structures between α- and β-GOS remain to be explored. In addition, it has been 
shown that different subjects can have a diametrically different metabolic response to the same food 
[49]; thus, to efficiently make use of e.g. GOS in human nutrition, a personalized approach might be 
required. 
 In conclusion, we demonstrate that supplementing a Western-type diet with GOS reduced the 
rate of intestinal fat absorption and thereby resulted in lower body weight gain, less adiposity, reduced 
insulin resistance and a less atherogenic plasma lipid profile. Although further studies in humans seem 
warranted to substantiate these effects, our work indicates that GOS supplements could offer an 
attractive option to reduce metabolic syndrome-related disease risk, one of the major health burdens 
of our times. 
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Figure 1: GOS supplementation reduces the development of metabolic syndrome related disease 
phenotypes. (A) body weight gain; (B) food intake at the end of the dietary intervention; (C) fat mass; 
(D) adipose fat depots; (E) glucose tolerance test (GTT) performed at the end of the dietary 
intervention on 6 h-fasted mice; (F) insulin tolerance test (ITT) performed at the end of the dietary 
intervention on 4 h-fasted mice; (G) total glucose area under the curve (AUC) of the ITT; (H) non-
fasted plasma cholesterol; (I) FPLC profiles; (J) triglycerides at the time sacrifice; (K) liver/body 
weight ratio; (L) hepatic triglyceride and (M) hepatic total cholesterol  at the end of the dietary 
intervention. Data are presented as mean ± SEM; N=8 for each group. Statistically significant 
differences are indicated as *p<0.05; **p<0.01, ***p<0.001. 
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Figure 2: GOS supplementation does not alter energy metabolism. (A) representative images from 
electron microscopy of brown adipose tissue (BAT). Ld: lipid droplet, m: mitochondria, bar=10µm;  
(B) mRNA expression in BAT; (C) respiratory exchange ratio (RER); (D) RER during light hours; (E) 
RER during dark hours; (F) energy expenditure (EE) during light hours; (G) EE during dark hours. 
Data are presented as mean ± SEM; N=8 for each group. Statistically significant differences are 
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Figure 3: GOS supplementation alters fecal sterol excretion. (A) 24-hours fecal mass output to body 
weight ratio at the end of the dietary intervention; (B) fecal neutral sterol excretion; (C) total fecal bile 
acid (BA) excretion; (D) fecal excretion rates of individual bile acid species; (E) plasma total BA; (F) 
plasma bile acid profiles. Data are presented as mean ± SEM; N=8 for each group. Statistically 
significant differences are indicated as *p<0.05; **p<0.01, ***p<0.001. 
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Figure 4: Plasma triglycerides during an oral fat absorption test. (A) 0 hour (B) 2 hour (C) 4 hour. 
Data are presented as mean ± SEM; N=8 for each group. Statistically significant differences are 
indicated as *p<0.05; **p<0.01. 
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Figure 5: GOS induces a favorable shift in the cecal microbiota composition. (A) LefSe cladogram 
showing differentially abundant phylum, class, order, family and genus level taxa between GOS and 
control treatment groups; (B) RDA triplot showing spatial distribution of cecal microbiota samples 
color-coded and enveloped by treatment group. The fifteen best fitting genus level taxa are projected 
on the graph. The percentage of total variance explained by first (constrained) and second 
(unconstrained) canonical axes are included indicating a strong effect of the diet. (C) Heatmap of 
correlations between relative abundance of genus level microbial taxa and various metabolic 
parameters. Red boxes indicate positive and blue negative correlations. Correlations that did not pass 
the cutoff of p<0.05 and the correlation threshold=0.7 are indicated with yellow boxes. Abbreviations: 
GLP-1 (Glucagon-like peptide-1), NS (neutral sterol), g-MCA (ω-muricholic acid), TBA (total bile 
acids), a-MCA (α-muricholic acid), HDCA (hyodeoxycholic acid) and DCA (deoxycholic acid).  
NOTE: When the taxonomic assignment was not available at genus level classification, the lowest 
classifiable taxonomy assignment was used instead and unidentified genus was indicated with “g_g”.  
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Tissues were excised during sacrifice and stored at -80ºC. 
Quantitative real-time PCR was performed as described in 
methods. Each gene is expressed as a ratio to the 
housekeeping gene 36B4 and further normalized to the 
expression level of the respective control group. Data 
presented as means ± SD; at least N=8 for each group. 
Statistically significant differences are indicated as 








Hmgcoar 1.00±0.44 0.80±0.32 
Cyp7a1 1.00±0.32 0.67±0.41 
Cyp8b1 1.00±0.31 0.62±0.21** 
Cyp27 1.00±0.09 1.02±0.15 
Srebp1c 1.00±0.27 1.02±0.48 
Ldlr 1.00±0.18 0.81±0.16 
Srebp2 1.00±0.10 0.82±0.17* 
Proximal intestine 
Apo C3 1.00±0.26 0.93±0.18 
GLP-1 1.00±0.11 1.66±0.46*** 
Mttp 1.00±0.19 1.09±0.34 
Distal intestine 
Asbt 1.00±0.27 1.45±0.34 
Fgf15 1.00±0.31 0.74±0.28 
White adipose tissue 
TNF α 1.00±1.23  0.68±0.87 
UCP1 1.00±0.35  1.14±0.31 
